Catamaran Bio, a biotech developing off-the-shelf CAR-NK cell therapies to treat cancer, has appointed Joseph Gold, PhD, as Vice President, Technical Operations and Manufacturing.
Dr. Gold has more than 25 years of experience in cell and gene therapy process development and GMP manufacturing. As head of Technical Operations and Manufacturing at Catamaran, he will lead the development of key aspects of the company’s Tailwind Platform, including transposon-based NK cell engineering, process development and scale-up, as well as GMP manufacturing of Catamaran’s CAR-NK product candidates.
“We are thrilled to have Joe join our senior leadership team. Joe has a very successful track record of managing and enabling the manufacture of cell therapy products through the entire development cycle, and his expertise will help ensure that our innovative CAR-NK cell therapies reach patients as soon as possible,” said Alvin Shih, MD, President and Chief Executive Officer of Catamaran Bio.
Prior to his new role, Dr. Gold was Senior Director of Manufacturing for the Center for Biomedicine and Genetics at the City of Hope Cancer Center, where he was responsible for managing process development and GMP manufacturing of cell and gene therapy products for both internal users and external clients.
In this role at City of Hope, he led multiple external collaborations to advance cancer research programs for cell therapies and managed a designated cell production facility.
Previously, he was Assistant Director of Translational Research at the Stanford University Cardiovascular Institute.
Dr. Gold began his career in biotech with Geron Corporation, where he served in several leadership roles. He is an inventor on more than 15 patents related to cell therapy and regenerative medicine and has authored more than 30 peer-reviewed publications. Dr. Gold earned a BS from the University of Pennsylvania and a PhD in cell and developmental biology from Harvard University.